Five-Year Pharmacovigilance Study Confirms Safety of NTC's Fixed-Dose Eye Drops for Post-Cataract Surgery
核心洞察
A five-year pharmacovigilance study analyzing nearly 4 million patients across 60 countries confirms the excellent safety profile of NTC's fixed-dose combination eye drops containing dexamethasone and levofloxacin for post-cataract surgery care.
The study identified only 53 adverse drug reactions in 25 patients between 2020 and 2024, with 74% being non-serious and more than half deemed unlikely related to the product.
No cases of endophthalmitis, a severe post-surgical eye infection, were reported, supporting the seven-day treatment regimen that improves patient adherence while minimizing antibiotic resistance risks.
A comprehensive five-year pharmacovigilance study has confirmed the excellent safety profile of NTC's fixed-dose combination eye drops containing dexamethasone and levofloxacin, used for preventing inflammation and infection following cataract surgery in adults. The study analyzed safety data from nearly 4 million patients across approximately 60 countries worldwide who were treated with this drug between 2020 and 2024.
Study Methodology and Findings
Conducted by Italian researchers and supported by NTC, the study analyzed public safety data registered in the adrreports.eu portal, which collects safety reports from EudraVigilance, the European Medicines Agency's official adverse drug reaction (ADR) database. The comprehensive analysis identified only 53 ADRs occurring in 25 patients over the four-year study period.
The key findings demonstrate a remarkably favorable safety profile:
- 74% of ADRs were classified as non-serious
- More than half of the reported reactions were deemed unlikely to be related to the product
- The most frequently reported events were mild reactions involving the eye or skin, which are expected outcomes for a topically administered ophthalmic solution
- Notably, no cases of endophthalmitis, a severe and rare infection that can occur following eye surgery, were reported
Clinical Significance and Expert Commentary
"This is the first international pharmacovigilance study focused specifically on a fixed-dose eye drop combining an antibiotic and an anti-inflammatory steroid," said Dr. Giorgio Ciprandi, senior author of the publication. "Its wide usage and favorable safety profile make of it a valuable option in the modern management of post-cataract patients."
The study's findings support the current recommendation of a short-term, seven-day treatment course, which improves patient adherence and limits the risk of side effects or antibiotic resistance. This simplified regimen represents a significant advancement in post-operative care, reducing unnecessary exposure to antibiotics while minimizing risks associated with prolonged steroid use.
Regulatory Impact and Market Authorization
The consistent safety profile demonstrated in this study has contributed to the product receiving marketing authorization renewal from European regulatory authorities. Since its initial approval in 2020, this innovative combination has provided patients with a streamlined treatment approach that addresses both inflammation prevention and infection control in a single formulation.
Alessandro Colombo, Chief Scientific Officer at NTC, emphasized the broader implications of the research: "This analysis confirms how continuous safety monitoring is essential to protect patients and support clinicians based on safety information collected from the spontaneous reporting."
Clinical Context and Treatment Landscape
Cataract surgery remains the most common ophthalmic procedure worldwide, making post-operative management critical to ensure optimal recovery outcomes. The fixed-dose combination of dexamethasone 1mg/mL and levofloxacin 5mg/mL represents a significant advancement in post-surgical care, offering both anti-inflammatory and antibiotic properties in a single eye drop solution.
The study highlights the importance of pharmacovigilance in evaluating medicines after market approval, demonstrating how continuous safety monitoring contributes to evidence-based clinical practice and patient protection. The comprehensive nature of this analysis, encompassing data from multiple countries and millions of patients, provides robust evidence for the safety profile of this therapeutic approach in post-cataract surgery management.